Skip to main content

Volume 25 - Issue 1 - January 2017

Department

Derm Dx
01/20/2017
In this case, a 28-year-old woman presented for an initial evaluation of a “rash” on her neck of 1-year duration.
In this case, a 28-year-old woman presented for an initial evaluation of a “rash” on her neck of 1-year duration.
In this case, a 28-year-old...
01/20/2017
The Dermatologist
Research in Review
01/20/2017
This article provides an updated review of health implications and regulatory issues pertaining to parabens.
This article provides an updated review of health implications and regulatory issues pertaining to parabens.
This article provides an updated...
01/20/2017
The Dermatologist

Column

Spotlight
01/20/2017
Charles Lynde, MD, FRCPC, is medical director of the Lynde Institute for Dermatology and Lynderm Research.  
Charles Lynde, MD, FRCPC, is medical director of the Lynde Institute for Dermatology and Lynderm Research.  
Charles Lynde, MD, FRCPC, is...
01/20/2017
The Dermatologist
Chief Medical Editor Message
01/20/2017
Dermatologists’ accomplishments and their devotion to patients continue to amaze me.
Dermatologists’ accomplishments and their devotion to patients continue to amaze me.
Dermatologists’ accomplishments...
01/20/2017
The Dermatologist
Voices
12/27/2016
Pharmaceutical compounding can fill the void and help patients` needs when it comes to prescription prices.
Pharmaceutical compounding can fill the void and help patients` needs when it comes to prescription prices.
Pharmaceutical compounding can...
12/27/2016
The Dermatologist
01/20/2017
Two new dermal integration technology-based products from IntraDerm Pharmaceuticals, a division of Oculus Innovative Sciences, Inc, are available in the United States.
Two new dermal integration technology-based products from IntraDerm Pharmaceuticals, a division of Oculus Innovative Sciences, Inc, are available in the United States.
Two new dermal integration...
01/20/2017
The Dermatologist
01/20/2017
Crisaborole (Eucrisa) ointment received FDA approval to treat mild to moderate eczema (atopic dermatitis) in patients aged 2 years and older.
Crisaborole (Eucrisa) ointment received FDA approval to treat mild to moderate eczema (atopic dermatitis) in patients aged 2 years and older.
Crisaborole (Eucrisa) ointment...
01/20/2017
The Dermatologist